Speakers:

Barbara W. Unger

President, Unger Consulting

Areas examined in this report:

  • Data from 2019 UK MHRA inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data